From the era of genome analysis to the era of genomic drug discovery: A pioneering example of rheumatoid arthritis

Clinical Genetics

Volumn 86, Issue 5, 2014, Pages 432-440

  Okada, Y ^a,b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Institute of Physical and Chemical Research   (Japan)

Author keywords

Genetics driven drug repositioning; Genetics driven genomic drug discovery; Genome wide association study; Pharmacogenomics; Rheumatoid arthritis

Indexed keywords

DRUG DEVELOPMENT; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; GENOMICS; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; DRUG DISCOVERY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX;

EID: 84911498917     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12465     Document Type: Review

References (77)

1. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011: 365: 2205-2219.
2. Seldin MF, Amos CI, Ward R et al. The genetics revolution and the assault on rheumatoid arthritis. Arthritis Rheum 1999: 42: 1071-1079.
3. Suzuki A, Yamada R, Chang X et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003: 34: 395-402.
4. Begovich AB, Carlton VE, Honigberg LA et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004: 75: 330-337.
5. The WTCCC. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 2007: 447: 661-678.
6. Plenge RM, Cotsapas C, Davies L et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007: 39: 1477-1482.
7. Raychaudhuri S, Remmers EF, Lee AT et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008: 40: 1216-1223.
8. Gregersen PK, Amos CI, Lee AT et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 2009: 41: 820-823.
9. Stahl EA, Raychaudhuri S, Remmers EF et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010: 42: 508-514.
10. Kochi Y, Okada Y, Suzuki A et al. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 2010: 42: 515-519.
11. Okada Y, Terao C, Ikari K et al. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet 2012: 44: 511-516.
12. Eyre S, Bowes J, Diogo D et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet 2012: 44: 1336-1340.
13. Okada Y, Wu D, Trynka G et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014: 506: 376-381.
14. Stahl EA, Wegmann D, Trynka G et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet 2012: 44: 483-489.
15. Deighton CM, Walker DJ, Griffiths ID et al. The contribution of HLA to rheumatoid arthritis. Clin Genet 1989: 36: 178-182.
16. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987: 30: 1205-1213.
17. Kazkaz L, Marotte H, Hamwi M et al. Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope. Ann Rheum Dis 2007: 66: 195-201.
18. Okada Y, Yamada R, Suzuki A et al. Contribution of a haplotype in the HLA region to anti-cyclic citrullinated peptide antibody positivity in rheumatoid arthritis, independently of HLA-DRB1. Arthritis Rheum 2009: 60: 3582-3590.
19. Okada Y, Suzuki A, Yamada R et al. HLA-DRB1*0901 lowers anti-cyclic citrullinated peptide antibody levels in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2010: 69: 1569-1570.
20. Neogi T, Aletaha D, Silman AJ et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report. Arthritis Rheum 2010: 62: 2582-2591.
21. Jia X, Han B, Onengut-Gumuscu S et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 2013: 8: e64683.
22. Raychaudhuri S, Sandor C, Stahl EA et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012: 44: 291-296.
23. Han B, Diogo D, Eyre S et al. Fine mapping seronegative and seropositive rheumatoid arthritis to shared and distinct HLA alleles by adjusting for the effects of heterogeneity. Am J Hum Genet 2014: 94: 522-532.
24. Okada Y, Kim K, Han B et al. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum Mol Genet 2014: doi: 10.1093/hmg/ddu387.
25. Kochi Y, Yamada R, Kobayashi K et al. Analysis of single-nucleotide polymorphisms in Japanese rheumatoid arthritis patients shows additional susceptibility markers besides the classic shared epitope susceptibility sequences. Arthritis Rheum 2004: 50: 63-71.
26. Pillai NE, Okada Y, Ong RT et al. Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations. Hum Mol Genet 2014: 23: 4443-4451.
27. The International HapMap Consortium. The International HapMap Project. Nature 2003: 426: 789-796.
28. Hindorff LA, Sethupathy P, Junkins HA et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009: 106: 9362-9367.
29. Ozaki K, Ohnishi Y, Iida A et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002: 32: 650-654.
30. Thomas DC, Haile RW, Duggan D. Recent developments in genomewide association scans: a workshop summary and review. Am J Hum Genet 2005: 77: 337-345.
31. Balding DJ, Bishop M, Cannings C. Handbook of statistical genetics, 3rd edn. Wiley, NJ, USA, 2007.
32. Diogo D, Okada Y, Plenge RM. Genome-wide association studies to advance our understanding of critical cell types and pathways in rheumatoid arthritis: recent findings and challenges. Curr Opin Rheumatol 2014: 26: 85-92.
33. Zuk O, Hechter E, Sunyaev SR et al. The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci U S A 2012: 109: 1193-1198.
34. Diogo D, Kurreeman F, Stahl EA et al. Rare, low-frequency, and common variants in the protein-coding sequence of biological candidate genes from GWASs contribute to risk of rheumatoid arthritis. Am J Hum Genet 2013: 92: 15-27.
35. Okada Y, Plenge RM. Entering the age of whole-exome sequencing in rheumatic diseases: novel insights into disease pathogenicity. Arthritis Rheum 2013: 65: 1975-1979.
36. Okada Y, Diogo D, Greenberg JD et al. Integration of sequence data from a consanguineous family with genetic data from an outbred population identifies PLB1 as a candidate rheumatoid arthritis risk gene. PLoS One 2014: 9: e87645.
37. Zuk O, Schaffner SF, Samocha K et al. Searching for missing heritability: designing rare variant association studies. Proc Natl Acad Sci U S A 2014: 111: E455-E464.
38. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010: 38: e164.
39. Westra HJ, Peters MJ, Esko T et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet 2013: 45: 1238-1243.
40. Raj T, Rothamel K, Mostafavi S et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 2014: 344: 519-523.
41. Okada Y, Kamatani Y. Common genetic factors for hematological traits in humans. J Hum Genet 2012: 57: 161-169.
42. Raychaudhuri S, Plenge RM, Rossin EJ et al. Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. PLoS Genet 2009: 5: e1000534.
43. Rossin EJ, Lage K, Raychaudhuri S et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 2011: 7: e1001273.
44. Trynka G, Sandor C, Han B et al. Chromatin marks identify critical cell types for fine mapping complex trait variants. Nat Genet 2013: 45: 124-130.
45. Forbes SA, Bindal N, Bamford S et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011: 39: D945-D950.
46. Eppig JT, Blake JA, Bult CJ et al. The Mouse Genome Database (MGD): comprehensive resource for genetics and genomics of the laboratory mouse. Nucleic Acids Res 2012: 40: D881-D886.
47. Segre AV, Groop L, Mootha VK et al. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet 2010: 6: e1001058.
48. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013: 12: 581-594.
49. Sanseau P, Agarwal P, Barnes MR et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol 2012: 30: 317-320.
50. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010: 9: 203-214.
51. Petrides F, Shearston K, Chatelais M et al. The promises of PCSK9 inhibition. Curr Opin Lipidol 2013: 24: 307-312.
52. Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med 2013: 64: 325-337.
53. Sekine C, Sugihara T, Miyake S et al. Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors. J Immunol 2008: 180: 1954-1961.
54. Hudson TJ, Anderson W, Artez A et al. International network of cancer genome projects. Nature 2010: 464: 993-998.
55. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008: 455: 1061-1068.
56. Lawrence MS, Stojanov P, Mermel CH et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014: 505: 495-501.
57. Robinson J, Halliwell JA, McWilliam H et al. The IMGT/HLA database. Nucleic Acids Res 2013: 41: D1222-D1227.
58. Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. Nat Methods 2010: 7: 248-249.
59. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009: 4: 1073-1081.
60. Davydov EV, Goode DL, Sirota M et al. Identifying a high fraction of the human genome to be under selective constraint using GERP++. PLoS Comput Biol 2010: 6: e1001025.
61. GTEx Consortium. The genotype-tissue expression (GTEx) project. Nat Genet 2013: 45: 580-585.
62. Bernstein BE, Birney E, Dunham I et al. An integrated encyclopedia of DNA elements in the human genome. Nature 2012: 489: 57-74.
63. Bernstein BE, Stamatoyannopoulos JA, Costello JF et al. The NIH roadmap epigenomics mapping consortium. Nat Biotechnol 2010: 28: 1045-1048.
64. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012: 40: D930-D934.
65. Geer LY, Marchler-Bauer A, Geer RC et al. The NCBI bioSystems database. Nucleic Acids Res 2010: 38: D492-D496.
66. Kanehisa M, Goto S, Sato Y et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014: 42: D199-D205.
67. Croft D, Mundo AF, Haw R et al. The Reactome pathway knowledgebase. Nucleic Acids Res 2014: 42: D472-D477.
68. Ashburner M, Ball CA, Blake JA et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000: 25: 25-29.
69. Zhang QC, Petrey D, Garzon JI et al. PrePPI: a structure-informed database of protein-protein interactions. Nucleic Acids Res 2013: 41: D828-D833.
70. Lage K, Karlberg EO, Storling ZM et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol 2007: 25: 309-316.
71. Franceschini A, Szklarczyk D, Frankild S et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013: 41: D808-D815.
72. Sherman BT, Huang W da, Tan Q et al. DAVID knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics 2007: 8: 426.
73. Lee PH, O'Dushlaine C, Thomas B et al. INRICH: interval-based enrichment analysis for genome-wide association studies. Bioinformatics 2012: 28: 1797-1799.
74. Knox C, Law V, Jewison T et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011: 39: D1035-D1041.
75. Zhu F, Shi Z, Qin C et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 2012: 40: D1128-D1136.
76. Kuhn M, Szklarczyk D, Franceschini A et al. STITCH 3: zooming in on protein-chemical interactions. Nucleic Acids Res 2012: 40: D876-D880.
77. Thorn CF, Klein TE, Altman RB. PharmGKB: the pharmacogenomics knowledge base. Methods Mol Biol 2013: 1015: 311-320.